Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

legal action

- PMLiVE

J&J gets FDA panel backing for canagliflozin

Moves ahead of BMS/AZ’s Forxiga in race for US approval as first in new class of diabetes drug

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

- PMLiVE

Lilly pays $29m to settle foreign bribery charges

US Securities and Exchange Commission charges centre on activities in Russia, China, Brazil and Poland

- PMLiVE

Amgen offers $762m to end Aranesp lawsuits

Pleads guilty to illegal marketing of anaemia drug

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

Gorsky named chairman of J&J

Completes transition from former CEO and chair Bell Weldon

- PMLiVE

J&J’s TB drug moves closer to US approval

Bedaquiline recommended as treatment for multidrug resistant forms of the disease

Building brand strength – Part 1

While we analyse the full results of the Iconic Brands Survey, we kick off with the first in our series looking at the hot buttons that will drive the pharma...

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

- PMLiVE

UCLA’s Eugene Washington joins J&J board

Health policy specialist is also chair of government body to develop comparative effectiveness research programme

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

- PMLiVE

Boehringer pays $95m to settle illegal marketing claims

Former sales rep whistleblower receives $17m from US federal government

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links